In this free webinar, attendees will learn from three thought leaders as they share their knowledge of adoptive T-cell therapies across the entire spectrum of development. The speakers will discuss strategies for assessing safety and possible efficacy to navigate regulatory pathways to the clinic and the role of biomarkers used to assess and monitor pharmacokinetics of the treatment dosing, level of the target cell population and other monitors of treatment efficacy.
TORONTO (PRWEB) May 06, 2020
Cancer remains one of the leading causes of mortality worldwide, but impressive advances in adoptive T-cell therapies, such as chimeric antigen receptor (CAR) T-cell immunotherapies, have led to drug development breakthroughs that offer new hope to many patients. However, the development pathway for these engineered cell-based therapies faces several unique challenges, particularly with safety assessment and medical monitoring.
Join this educational webinar to learn how to create successful development paths for CAR-T and T-cell receptor (TCR) therapies. Along with a historical overview of these engineered T-cell products, published guidelines will be covered and how development is shaped by the attributes of the therapeutic itself will be discussed.
The speakers will also cover safety biomarkers that can help predict cytokine release syndrome (CRS) or neurologic adverse events and will discuss predictive biomarkers that can assist with patient stratification. They will also provide insights on handling immune-related adverse events and best practices in toxicity management to manage ongoing safety monitoring challenges.
- Brian E. McIntosh, PhD, Study Director and Scientific Lead, Cell, Gene and Regenerative Therapies
- Akanksha Gupta, PhD, Head, Immunology, Biomarker Solution Center
- Carlo Lanza, MD, PhD, Executive Medical Officer at Covance and Subject Matter Expert in Hematology Oncology
This webinar is part of a scientific series Covance is offering focused on trends, challenges and opportunities associated with current and future applications in Oncology. Learn more and register for upcoming webinars on topics such as adoptive cell therapies, biomarker technologies for the detection of cancer driver mutations, novel targeted therapies and more.
For more information or to register for this event, visit Autologous CAR-T Development: Safety Assessment and Monitoring in Preclinical and Clinical Programs.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
For the original version on PRWeb visit: https://www.prweb.com/releases/autologous_car_t_development_safety_assessment_and_monitoring_in_preclinical_and_clinical_programs_upcoming_webinar_hosted_by_xtalks/prweb17100126.htm